share_log

Needham Reiterates Buy on Immuneering, Maintains $15 Price Target

Needham Reiterates Buy on Immuneering, Maintains $15 Price Target

Needham重新买入Immuneering股票,并维持15美元的目标价。
Benzinga ·  2024/11/14 18:20  · 评级/大行评级

Needham analyst Ami Fadia reiterates Immuneering (NASDAQ:IMRX) with a Buy and maintains $15 price target.

尼德姆分析师阿米·法迪亚重申Immuneering(纳斯达克股票代码:IMRX)的买入并维持15美元的目标股价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发